The percentage of those with early-onset diverticulitis admitted for complicated diverticulitis went from 18.5% to 28.2% from 2005 to 2020.

Physicians with H-1B-sponsored visas accounted for 0.97% of physicians in the United States in fiscal year 2024.

Developers of biosimilars will no longer be required to conduct clinical trials to prove effectiveness for FDA approval.

Primary OS analysis results from STELLAR-303 showed zanzalintinib + atezolizumab improved OS vs regorafenib in metastatic colorectal cancer.

Nearly two-thirds of asymptomatic adults in a US safety-net health care system tested positive for Helicobacter pylori antibodies.

The probability of developing ocular EIMs was comparable across treatment classes among patients with HLA-B27-associated diseases.

Individuals with MetALD vs MASLD have significantly higher risks for liver-related events, liver cancer, and extrahepatic cancers.

Ustekinumab and vedolizumab have comparable safety and efficacy in older and younger adults with IBD, indicating that age should not be a deterrent for treatment.

Moderate-to-vigorous physical activity guideline adherence was associated with a 22% and 17% lower CHD risk in women and men, respectively.

The presence of metabolic dysfunction-associated steatotic liver disease may be a predictor of disease trajectory in patients with MACE.

There was a significant association between early age of natural menopause vs late age and metabolic syndrome.

Tetrachloroethylene (PCE) exposure was linked to a tripled risk for significant liver fibrosis, with a dose-dependent effect.